Clot structure of ET and PV
Research type
Research Study
Full title
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: influence on the clot structure.
IRAS ID
206405
Contact name
Claire N Harrison
Contact email
Sponsor organisation
Geneva University Hospitals
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
Myeloproliferative neoplasms (MPN) such as Polycythemia Vera (PV) and, Essential Thrombocythaemia (ET) are rare diseases (precancerous conditions) associated with an increased risk of clot (thrombosis) in blood vessels.
Routine clotting (haemostasis) blood analysis are usually normal and are useless to demonstrate if a patient should be considered more or less at risk of clot (thrombosis) development.
However, previous evidence in scientific publications suggests that very specific clotting analysis (global coagulation tests such as thrombin generation or thromboelastometry) are able to identify patients with MPN that are at increase risk of clot (thrombosis) formation.
Goals of PV and ET treatments are to control blood count (red cells, platelets) to reduce the risk of clot (thrombosis) formation. It is currently unknown if treatments that were used for ET and PV are able to modify the predisposition of clot formation (hypercoagulable state) that is observed in those diseases, and if there is difference between drugs.
To evaluate impact of MPN treatment on predisposition of clot formation, we propose to evaluate specific clotting analysis, depending on the treatment.
This study is an observational study that will include PV and ET patients (≥18 years). Recruiting sites will be the haematology department at Guy's Hospital (London, UK) and at the Geneva University Hospitals (Geneva, CH). We are expecting to recruit 80 patients in one year.
REC name
West of Scotland REC 4
REC reference
17/WS/0111
Date of REC Opinion
14 Jun 2017
REC opinion
Further Information Favourable Opinion